辉瑞公司6月30日宣布新型抗菌药物思福诺(注射用氨曲南阿维巴坦钠以下简称“氨曲南/阿维巴坦”)获得国家药品监督管理局正式

智通财经
30 Jun
辉瑞公司6月30日宣布新型抗菌药物思福诺(注射用氨曲南阿维巴坦钠以下简称“氨曲南/阿维巴坦”)获得国家药品监督管理局正式批准用于治疗由革兰阴性菌引起的治疗药物选择有限或无替代治疗的成人复杂性腹腔内感染(cIAI)医院获得性肺炎(HAP)包括呼吸机相关性肺炎(VAP)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10